Suggest Saving PCSK9 Inhibitors for Patients With Familial Hypercholesterolemia

July 2016

You'll see Praluent ( PRAL-you-ent, alirocumab), the new PCSK9 inhibitor for high cholesterol in Canada.

It's the second PCSK9 inhibitor after Repatha (evolocumab).

These work by preventing PCSK9...proprotein convertase subtilisin kexin type 9...from binding and degrading LDL receptors in the liver. This allows the liver to clear more LDL cholesterol from the blood.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Infectious Diseases Recommend Avoiding Quinolones for Uncomplicated Urinary Tract Infections
Substance Use Disorder Report Suspected Loperamide Misuse to Canada Vigilance
Cardiology Suggest Saving PCSK9 Inhibitors for Patients With Familial Hypercholesterolemia
Chronic Pain Recommend Avoiding Long-Acting Opioids When Starting Pain Treatment
Encourage Prescribers to Write Long-Acting Calcium Channel Blockers Generically
Insomnia Consider Melatonin an Option for Sleep in Elderly Patients
Smoking Cessation Give "Vapers" Resources to Quit E-Cigarettes
Anticoagulants Recommend Praxbind to Reverse Life-threatening Bleeding in Patients on Pradaxa
Anticoagulants Recommend Using Actual Weight to Dose Enoxaparin in Obese Patients
Communication Explain the "Why" to Encourage Patients to Talk Openly
Travel Medicine Tell Travellers Flomax is the Name for an NSAID in Italy

Suggest Saving PCSK9 Inhibitors for Patients With Familial Hypercholesterolemia

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents